Mapping the sclerostin–LRP4 binding interface identifies critical interaction hotspots in loops 1 and 3 of sclerostin

Svetlana Katchkovsky,Reut Meiri,Shiran Lacham‐Hartman,Yaron Orenstein,Noam Levaot,Niv Papo

DOI: https://doi.org/10.1002/1873-3468.15033

2024-10-25

FEBS Letters

Abstract:The interaction between sclerostin and low‐density lipoprotein receptor‐related protein 4 (LRP4) inhibits bone formation by disrupting the Wnt/β‐catenin pathway. By screening a library of sclerostin variants, we identified key mutations that decrease the binding affinity to LRP4, specifically at positions K75 and V136. These findings highlight critical binding sites for developing therapies to enhance bone formation. The interaction of sclerostin (Scl) with the low‐density lipoprotein receptor‐related protein 4 (LRP4) leads to a marked reduction in bone formation by inhibiting the Wnt/β‐catenin pathway. To characterize the Scl–LRP4 binding interface, we sorted a combinatorial library of Scl variants and isolated variants with reduced affinity to LRP4. We identified Scl single‐mutation variants enriched during the sorting process and verified their reduction in affinity toward LRP4—a reduction that was not a result of changes in the variants' secondary structure or stability. We found that Scl positions K75 (loop 1) and V136 (loop 3) are critical hotspots for binding to LRP4. Our findings establish the foundation for targeting these hotspots for developing novel therapeutic strategies to promote bone formation.

cell biology,biochemistry & molecular biology,biophysics